Return to homepagePandemic Pact

Benefit versus risk for anti-SARS-CoV-2 agents

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-019

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Prof. Munir Pirmohamed

  • Research Location

    United Kingdom

  • Lead Research Institution

    MRC Centre for Drug Safety Science at the University of Liverpool

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Investigating the likely effects of anti-SARS-CoV-2 agents at different parts of the viral life-cycle